Taking a Look at $KYMR:
An updated look at Kymera Therapeutics.
An updated look at Kymera Therapeutics.
1/ Management:
I have been in Kymera for about 9 months now. I think Nello Mainolfi has done a good job so far. Its still early stages so don't know how well he will navigate the regulatory and commercial aspects of the business.
I have been in Kymera for about 9 months now. I think Nello Mainolfi has done a good job so far. Its still early stages so don't know how well he will navigate the regulatory and commercial aspects of the business.
2/ Science:
Kymera is working on Targeted Protein Degradation. This uses the Proteasome of the cell to target and breakdown unwanted proteins. This can be harnessed to target proteins that can be therapeutic to inhibit.
Kymera is working on Targeted Protein Degradation. This uses the Proteasome of the cell to target and breakdown unwanted proteins. This can be harnessed to target proteins that can be therapeutic to inhibit.
3/ They are working on targets for immunology and oncology. Their first 2 drugs focus on IRAK4 which is part of the pathway for activation of Toll Like Receptors in immune cells. This blocks the production of key inflammatory cytokines like IL-1b.
4/ This has the potential to be the next great anti inflammatory drug like Humira. They are testing IRAK4 in HS, AD and RA. They are testing IRAK4 in combo with IMID in oncology indications for cancer driven by MyD88 driver mutations.
5/ Their third drug targets STAT3 which is part of the famous JAK/STAT pathway. They are focused on STAT3 for oncology and immunology indications like fibrosis. Their last drug is for MDM2 which inhibits p53. This is a potential target for p53 mutant cancers.
6/ Potential:
I think Kymera has a ton of potential depending how well these targets work in the possible indications. The IRAK4 alone in inflammation could do $3 billion to $5 billion in sales if it works well.
I think Kymera has a ton of potential depending how well these targets work in the possible indications. The IRAK4 alone in inflammation could do $3 billion to $5 billion in sales if it works well.
7/ It could go much higher if it turns out to be a powerful anti inflammatory drug. It can also do up to $1 billion in the MyD88 driven cancers.
8/ Its hard to estimate what STAT3 might do in revenues, but I would speculate upward of a few billion if it works as well as I think it could.
9/ Value:
Kymera seems cheap at just under $2 billion market cap for all the potential it has. They have $567 million in cash and burned $100 million in 2021. They have a good 2 years of cash as they move these programs into the clinic.
Kymera seems cheap at just under $2 billion market cap for all the potential it has. They have $567 million in cash and burned $100 million in 2021. They have a good 2 years of cash as they move these programs into the clinic.
10/ It is still very early, and a lot depends on the first efficacy data from the IRAK4 indications in HS and AD. If these programs are successful, this could prove to be a very cheap company at this valuation.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
